<DOC>
	<DOCNO>NCT00000723</DOCNO>
	<brief_summary>To determine safety toxicity high-dose systemic methotrexate ( MTX ) dexamethasone ( DEX ) combine zidovudine ( AZT ) brain irradiation patient AIDS-related primary central nervous system ( CNS ) lymphoma determine response rate survival treated patient . Also determine treatment inhibits HIV replication patient HIV culture and/or antigen positive ass incidence opportunistic infection patient Results radiation give patient AIDS-related high-grade CNS lymphoma disappointing , short survival time due infection complication . However , complete response document radiation patient . High-dose MTX use improve possibility great antineoplastic response obtain radiation alone . Since underlie immunodeficiency state affect therapy direct lymphoma , patient still prone life-threatening opportunistic infection relapse lymphomatous disease within CNS . Accordingly , AZT also use attempt alter overall natural history disease .</brief_summary>
	<brief_title>The Use Chemotherapy Plus Radiotherapy Plus Azidothymidine Patients With AIDS-Related Lymph Node Cancer</brief_title>
	<detailed_description>Results radiation give patient AIDS-related high-grade CNS lymphoma disappointing , short survival time due infection complication . However , complete response document radiation patient . High-dose MTX use improve possibility great antineoplastic response obtain radiation alone . Since underlie immunodeficiency state affect therapy direct lymphoma , patient still prone life-threatening opportunistic infection relapse lymphomatous disease within CNS . Accordingly , AZT also use attempt alter overall natural history disease . Radiation begin day 1 therapy . Patients receive dexamethasone orally ( PO ) intravenous injection ( IV ) day 1-10 . MTX IV 6 hour weekly total 4 dos start 1 week completion cranial radiation . Leucovorin ( LCV ) IV PO begin 6 hour MTX complete 6 hour 8 dos . AZT awake start day 1 therapy continue 52 week . Patients reevaluate computerized tomography ( CT ) magnetic resonance imaging ( MRI ) scan brain conclusion radiation therapy systemic treatment , 6 10 week respectively . If complete partial response ( CR PR ) , patient remain study continue receive AZT ; stable disease response , patient take study . Reevaluation 16 week start study do . If CR PR , patient continue AZT 1 year . If change progression disease , patient develops evidence systemic lymphomatous disease , patient take study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Inclusion Criteria Patient must negative titer toxoplasmosis infectious etiology CNS disease . Prior Medication : Allowed : Zidovudine may continue per protocol specification . Exclusion Criteria Pathologic diagnosis lymphoma central nervous system ( CNS ) must confirm previous treatment allow . In participate institution CNS biopsy obtain , patient may consider eligible spaceoccupying lesion demonstrate computerized tomography magnetic resonance image negative titer toxoplasmosis negative response empiric therapy intracerebral toxoplasmosis negative workup infectious etiology CNS disease . Coexisting Condition : Patients follow exclude : Positive titer toxoplasmosis . Positive titer infectious etiology CNS disease . Acute intercurrent infection . A second active tumor nonmelanomatous skin cancer Kaposi 's sarcoma . Lymphomatous meningitis alone without mass lesion brain . Concurrent Medication : Excluded : Acetaminophen , nonsteroidal anti inflammatory agent , corticosteroid dexamethasone . Prior Medication : Excluded : Acetaminophen , nonsteroidal antiinflammatory agent , corticosteroid dexamethasone . Excluded within 2 week study entry : Immunomodulating agent . Excluded within 30 day study entry : Any investigational agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Leucovorin</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Combined Modality Therapy</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Brain Neoplasms</keyword>
</DOC>